

## Research Article

# T-Cell Response to Hepatitis B Core Antigen: Identification of Prior Exposure to and Confirmatory Testing for Screening for Anti-HBc

Patricia Araujo,<sup>1</sup> Roger Y. Dodd,<sup>2</sup> Flavia Latinni,<sup>3</sup> Renata Souza,<sup>4</sup>  
Ricardo Diaz,<sup>5</sup> and Jose Augusto Barreto<sup>6</sup>

<sup>1</sup> Infection Diseases Laboratory, Colsan/UNIFESP, Avenida Indianópolis, 1260 Indianópolis, São Paulo, SP, Brazil

<sup>2</sup> American Red Cross, USA

<sup>3</sup> Colsan, Technical and Research Department, Brazil

<sup>4</sup> Colsan, Quality Laboratory, Brazil

<sup>5</sup> Retrovirology Laboratory, UNIFESP, Brazil

<sup>6</sup> Colsan, Associação Beneficente de Coleta de Sangue, Head Colsan, Brazil

Correspondence should be addressed to Patricia Araujo; rba.patricia@gmail.com

Received 18 June 2013; Revised 8 September 2013; Accepted 8 September 2013

Academic Editor: Rajarshi Pal

Copyright © 2013 Patricia Araujo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** During routine donor screening in the blood bank, it is not uncommon to find isolated reactivity for anti-HBc in the absence of detectable HBV DNA in a first donation but absence of reactivity to anti-HBc in subsequent donations, suggesting a false-positive result for anti-HBc. **Study Design and Methods.** The blood donor population was screened between January 2010 and October 2011. We selected 2,126 donations positive only for anti-HBc from a total of 125,068 donations. During the process, OBI donors were identified, and their HBcAg-specific T-cell response was analyzed and compared to donors with chronic (HBsAg positive) and recovered (anti-HBc only) infection. We analyzed correlations between signal levels (Co/s) in the competitive assay for anti-HBc and HBV DNA detection. **Results.** In the 21-month study period, 21 blood donors with anti-HBc alone were identified as OBI (1 in each 5955 donors). The relevant finding was the observation that anti-HBc only subjects with Co/s  $\geq 0.1$  did not have either HBcAg-specific T-cells or detectable HBV DNA and OBI subjects presented with Co/s  $\leq 0.1$  and HBcAg T-cell response. In the subset of 21 OBI subjects, 9 donors remained positive for HBcAg T-cell response after four collections. In all 9 samples, we observed HBV DNA fluctuation. **Conclusion.** Our data suggest that HBcAg-specific T-cell response could be used to confirm anti-HBc serological status, distinguishing previous exposure to Hepatitis B virus from anti-HBc false-positive results.

## 1. Introduction

Hepatitis B virus (HBV) infection is an important global health problem [1, 2] especially in Asia, Africa, Southern Europe, and Latin America [3]. About 2 billion people are infected with HBV worldwide [4–7], among them, 400 million suffer chronic HBV infection [5]. In Brazil, the HBsAg positivity ranges from 1.6% to 8.5%, corresponding to approximately 3 to 16 million infected individuals [8–13]. The residual HBV risk in screened blood transfusion ranges from 1:10,700 [14] to 1:62,734 [15] and is markedly higher

compared to Europe [16], North America [17, 18], Australia [19], and Japan [20].

Further, the identification of blood donors with occult HBV infection (OBI) individuals negative for Hepatitis B antigen (HBsAg) with detectable circulating HBV DNA has created concern related to the safety of the blood supply [21, 22].

Hepatitis B virus continues to offer the greatest risk of transfusion-transmission infection despite HBsAg screening of blood donations. Residual risk of HBV transfusion-transmission results from occult HBV infection, window